TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RNAC stock, giving a Buy rating on August 8.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight the promising potential of Cartesian Therapeutics. The initiation of the Phase III AURORA trial, which began in May 2025, is a significant milestone for the company. This trial is expected to enroll rapidly, with potential data available by the end of 2026. The positive outcomes from the Phase IIb trial, particularly the deep and durable response of Descartes-08, support a high probability of success in the upcoming trial.
Descartes-08, a BCMA-targeting CAR-T therapy, stands out due to its mRNA-based design, offering controllable pharmacokinetics and pharmacodynamics, predictable half-life, and reduced toxicity. The therapy’s impressive performance in Myasthenia Gravis patients, with sustained improvements in MG-ADL and QMG scores over 12 months, further underscores its potential as a one-course treatment. These factors, combined with the therapy’s safety profile and value proposition, contribute to Tyler Van Buren’s optimistic outlook and Buy rating for Cartesian Therapeutics.
In another report released on August 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.